Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline

Simply Wall St.04-16 22:08

Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628109572?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-16 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628109572","market":"nz","top_or_hot":-1,"title":"Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline","media":"Simply Wall St.","content":"<div>\n<p>Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-16 22:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4006","symbol_name":"钢铁","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","article_id":"2628109572","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628109572","pubTimestamp":1776348536,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of its mesenchymal stromal cell therapies.\nSee our latest analysis for Mesoblast.\nAt a share price of A$2.24, Mesoblast has seen a 10.89% 1 month share price return and a 10.34% 7 day share price return. Over 90 days, the share price return is a 15.15% decline, while the 3 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4006":"钢铁","BK4022":"陆运","CAR":"安飞士","BK7501":"新冠治疗股","BK4230":"旅客陆运","BK7508":"医药生物股","MSB.AU":"MESOBLAST LTD","BK7067":"生物科技","MSB":"美莎比信托"},"translate_title":"Mesoblast(ASX：MSB)估值检查，因为新汽车技术许可针对更强大的细胞治疗管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1.5,"MSB":1.5,"CAR":1.5},"content_text":"Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of its mesenchymal stromal cell therapies. See our latest analysis for Mesoblast. At a share price of A$2.24, Mesoblast has seen a 10.89% 1 month share price return and a 10.34% 7 day share price return. Over 90 days, the share price return is a 15.15% decline, while the 3 year total shareholder return of 138.64% and 1 year total shareholder return of 35.76% indicate stronger longer term momentum. If Mesoblast’s recent clinical and licensing updates have caught your attention, it can also be useful to see what else is moving in related areas using our 10 healthcare AI stocks With Mesoblast trading at A$2.24, at a significant discount to analyst price targets and an indicated intrinsic discount of 26.93%, the key question is whether this reflects caution or if the market is underestimating its future growth potential. AdvertisementMost Popular Narrative: 42% Undervalued With Mesoblast at A$2.24 against a narrative fair value of A$3.83, the widely followed view prices in a sizable gap between market price and expected potential, built on a set of specific product and market assumptions.  The heart failure program for rexlemestrocel L, with RMAT designation and FDA feedback that existing trial data could support an accelerated approval filing alongside a planned confirmatory study, gives Mesoblast a potential entry into a very large cardiovascular market. Outcomes would primarily influence long term revenue scale and the path to sustainable earnings.  Read the complete narrative. Curious what kind of revenue ramp and margin shift would need to sit behind this story, and what future earnings multiple ties it all together. Result: Fair Value of A$3.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on Ryoncil gaining traction beyond early adopters, as well as on label expansions and pivotal trials avoiding delays or disappointing outcomes. Find out about the key risks to this Mesoblast narrative. Another way to look at the price While the SWS DCF model suggests Mesoblast at A$2.24 is undervalued versus an A$3.07 fair value, the same dataset shows analysts are not tightly aligned on forecasts. If the cash flow story is this sensitive to assumptions, it may be worth considering how much weight to place on a single fair value point. Look into how the SWS DCF model arrives at its fair value. MSB Discounted Cash Flow as at Apr 2026Next Steps With sentiment around Mesoblast mixed, this is a good time to look through the key numbers yourself and decide how you feel about the risk and reward trade off. To see what the market is currently optimistic about, take a closer look at the 3 key rewards Looking for more investment ideas? If Mesoblast is on your radar, it is worth lining it up against a few other focused sets of companies to see what really stands out.  Spot potential bargains early by scanning screener containing 14 high quality undiscovered gems that pair solid fundamentals with limited market attention. Prioritise resilience by reviewing 8 resilient stocks with low risk scores that score well on financial strength and business stability. Target quality at a reasonable price by checking 9 high quality undervalued stocks that combine stronger balance sheets with attractive valuations.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628109572","isCrawlerRequest":true}